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Pulmonary arterial hypertension (PAH) is rarely included in the differential diagnosis of cardiorespiratory
failure after pediatric hematopoietic stem cell transplant (HSCT) as the clinical presentation is nonspeciﬁc and
may mimic other etiologies. The pathogenesis of PAH in HSCT is poorly understood and the diagnosis requires
a high degree of suspicion. We describe 5 children diagnosed with PAH after allogeneic HSCT. All 5 patients
had prolonged clinical signs of transplantation-associated thrombotic microangiopathy (TA-TMA) when they
presented with hypoxemic respiratory failure and evidence of PAH. Four of the 5 patients had echocardio-
graphic evidence of PAH, and 1 patient was diagnosed with PAH only on autopsy. PAH was diagnosed
a median of 76 days (range, 56-101 days) after a diagnosis of TA-TMA. Despite aggressive medical manage-
ment, including inhaled nitric oxide, 4 of the 5 patients died. One patient recovered from PAH after 11 months
of sildenaﬁl therapy. Three of the 4 deceased patients had an autopsy performed, demonstrating severe
pulmonary vascular disease consistent with TA-TMA and severe PAH. We conclude that TA-TMA can be
associated with signiﬁcant pulmonary vascular injury presenting as hypoxemic respiratory failure with PAH
after HSCT. Pediatric patients with unexplained hypoxemia after HSCT should be evaluated for both trans-
plantation complications, TA-TMA and PAH, accordingly.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION HSCT recipientswithmultiple potential causes for respiratory
Pulmonary hypertension is rarely considered in the
differential diagnosis of cardiorespiratory failure after pedi-
atric hematopoietic stem cell transplant (HSCT). The
complication may occur as a primary pulmonary arterial
process or secondary to pulmonary venous hypertension,
hypoxia, or thromboembolism [1].
Pulmonary arterial hypertension (PAH) is a disorder
deﬁned by a progressive increase of pulmonary vascular
resistance leading to right ventricular failure and premature
death [2]. PAH is deﬁned by a pulmonary arterial pressure
over 25 mm Hg at rest and over 30 mm Hg during activity in
combination with an increase in pulmonary vascular resis-
tance over 3 Wood’s units [3]. Histopathologically, it is
characterized by vascular proliferation and remodeling of all
3 levels of the vessel wall with proliferative and obstructive
changes including endothelium, smooth muscle cells, and
ﬁbroblasts [3-7]. Pulmonary vasoconstriction is a signiﬁcant
early component in PAH [8]. Early in the disease course, PAH
may be asymptomatic or present with nonspeciﬁc symptoms
such as dyspnea on exertion and fatigue. This makes the
clinical diagnosis very challenging, especially in complexedgments on page 206.
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12.08.022disease [1]. Although transthoracic echocardiography is
an excellent noninvasive screening tool to estimate right
ventricle (RV) pressure and pulmonary artery (PA) pressure,
right heart catheterization with direct pressure measure-
ments remains thegold standard for thediagnosis of PAH [1,9-
12]. However, an RV pressure 50% of the systemic pressure
on a screening echocardiogram is highly suggestive of
elevatedPApressure inpatientswithnormal cardiac anatomy.
PAH has been reported in almost all forms of inherited
and acquired hemolytic anemias [13-15], but its incidence in
patients with HSCT-associated thrombotic microangiopathy
(TA-TMA) has not been described, with the exception of 2
brief case reports of pulmonary renal disease possibly asso-
ciated with thrombotic microangiopathy [16,17].
TA-TMA is a severe and multifactorial complication of
HSCT and occurs when endothelial injury causes micro-
angiopathic hemolytic anemia and platelet consumption,
resulting in thrombosis and ﬁbrin deposition in the micro-
circulation and end-organ injury. The kidney is the most
commonly affected organ, with other organ injury only
rarely reported [18]. Herein, we describe a case series of
5 pediatric allogeneic HSCT recipients diagnosed with
hypoxemic respiratory failure and PAH with clinical and
histologic evidence of pulmonary TA-TMA.
MATERIALS AND METHODS
After institutional review board approval, we reviewed the records of
209 consecutive HSCT recipients who underwent transplantation between
March 1, 2009, and April 30, 2011, at Cincinnati Children’s Hospital MedicalTransplantation.
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ﬁndings of pulmonary vascular disease. PAH was deﬁned as echocardio-
graphic evidence of right ventricular dysfunction, dilation, and/or elevated
pressure (RV pressure50% of the systemic pressure), or histologic evidence
of pulmonary vascular disease on lung biopsy or autopsy as evidenced by
vascular proliferation and remodeling of all 3 levels of the arteriolar wall
with obstructive changes including endothelial, smooth muscle cells, and
ﬁbroblasts. All patients with hypoxemic respiratory failure requiring
mechanical ventilation who were examined by echocardiogram or had lung
tissue available for histologic diagnosis were included in analysis.
Demographic, clinical, and laboratory information of identiﬁed patients
was abstracted from their medical records. All patients had a baseline pre-
transplantation electrocardiogram, echocardiogram, and chest computed
tomography scan. Baseline pulmonary function assessment was performed
by pulse oximetry or formal pulmonary function test, depending on the
patient’s age and ability to perform pulmonary function test testing within
30 days before undergoing HSCT. These studies were repeated only as
clinically indicated during the transplantation course. There were no
uniform guidelines for screening for pulmonary hypertension in patients
with hypoxemic respiratory failure; therefore, echocardiographic evalua-
tions were performed at the discretion of the treating physician.
TA-TMA diagnosis was made by the treating HSCT physician using
uniform published diagnostic criteria: de novo microangiopathic anemia
with the presence of schistocytes on peripheral blood smear, de novo
thrombocytopenia, elevated lactate dehydrogenase (LDH), low haptoglobin,
doubling of serum creatinine, evidence of neurologic symptoms, and/or
histologic evidence of microangiopathy on tissue biopsy or autopsy [19].
Because of age-dependent laboratory normal ranges for hemoglobin, LDH,
and serum creatinine, these tests were reported as abnormal for each
patient based on their values. Elevation in serum creatinine was reported as
doubling of serum creatinine from pretransplantation value for each patient.
Neurologic symptoms, if any, were deﬁned as a documented change in
mental status or seizures coinciding with diagnosis of TA-TMA. Acute graft-
versus-host disease (aGVHD) was graded according to the Glucksberg
criteria. Viremias were documented by detection of a virus in the blood
using quantitative PCR assays deﬁned as a viral load above the lower limit of
laboratory detection. Viral illness was deﬁned as PCR detection of a virus in
combination with clinical symptoms. All patients had uniform monitoring
and prophylactic and supportive care after their transplantation. Patients
who underwent HSCT requiring intensive care unit admission were co-
managed by the Critical Care and Bone Marrow Transplant Service.RESULTS
Of the 209 patients undergoing HSCT at our center during
this period, 21% (45 patients) developed hypoxemic respi-
ratory failure requiring mechanical ventilation, 87% of them
after allogeneic HSCT. Diagnostic echocardiographic studies
were performed in 73% (33 of 45 patients); of these, 15%
(5 of 33 patients) had clinical and/or histologic diagnosis of
PAH after HSCT. Demographic and HSCT treatment charac-
teristics for patients with pulmonary hypertension are
described in Table 1. All 5 patients were young children
who underwent allogeneic HSCT: 3 for immunodeﬁciency,
1 for bone marrow failure, and 1 for malignancy. The 3
patients with immunodeﬁciency received reduced intensityTable 1
Patient Demographics and Transplantation Characteristics
Patient Diagnosis Age (y) Gender Donor
Match
HSCT
Regimen
Chemotherap
1 XLP 1.8 Male URD 7/8 RIC Alemtuzumab
2 FA 5.8 Female MUD 8/8 MA Busulfan, ﬂud
3 HLH 0.6 Male URD 7/8 RIC Alemtuzumab
4 XLP 1.8 Male MSD 8/8 RIC Alemtuzumab
5 CML 10.4 Female MUD 8/8 MA Busulfan, cycl
HSCT indicates hematopoietic stem cell transplant; aGVHD, acute graft-versus-ho
proliferative syndrome; URD, unrelated donor; RIC, reduced intensity regimen;
regimen; ATG, antithymocyte globulin; BAL, bronchoalveolar lavage; HLH, hemoph
donor; MPV, metapneumovirus; CML, chronic myelogenous leukemia; EBV, Epsteiconditioning (RIC) regimen, and the remaining 2 patients
received a myeloablative (MA) conditioning regimen. All 5
patients had normal pretransplantation assessment of
cardiac and pulmonary function. Only 1 patient developed
aGVHD of the skin posttransplantation, whereas 3 of 5
patients had viral infections (Table 1).
All 5 patients required intensive care unit admission for
hypoxemic respiratory failure and mechanical ventilation.
PAH was diagnosed by echocardiography in 3 of 5 patients
within 24 hours of initiating mechanical ventilation. In the
remaining 2 patients, 1 was diagnosed with PAH by echo-
cardiogram 20 days after intubation, whereas the other was
noted to have evidence of pulmonary vascular disease only
on autopsy 33 days from the start of mechanical ventilation.
This patient had echocardiography done 1 month before his
death, which showed normal biventricular function and RV
pressure 28% of systemic, but echocardiography was not
repeated after the patient’s clinical deterioration. Only 1
patient underwent cardiac catheterization, which demon-
strated an elevated mean PA pressure and increased
pulmonary vascular resistance. All but 1 patient who was
diagnosed with pulmonary vascular disease on autopsy were
evaluated by a specialized pulmonary hypertension team.
The clinical presentationwas variable for the 5 patients in
this series. Two patients (patient 1 and 2) presented with
acute respiratory distress. Patient 1 presented to the emer-
gency department with acute hypoxemia 169 days after
transplantation. A bronchoalveolar lavage (BAL) was not
diagnostic, and his echocardiogram indicated severe
pulmonary hypertension with an RV pressure >90% of
systemic. Despite aggressive supportive care and therapy
with inhaled nitric oxide (iNO), he died within 24 hours.
Similarly, patient 2 presented with rapidly progressive
hypoxemia 79 days post-HSCT, leading to respiratory failure
without any documented infection. Her echocardiogramwas
notable for an RV pressure 80% of systemic. Her clinical status
worsened with progression to shock, despite therapy with
iNO and vasopressor support. She underwent emergent
cardiac catheterization with balloon atrial septostomy con-
ﬁrming severe PAH with a mean PA pressure of 58 mm Hg
and a pulmonary vascular resistance of 7 Wood’s units. The
septostomy procedure improved her cardiac output, but with
progressive hypoxia, her family elected to withdraw support
and she died within 24 hours of presentation.
In contrast, the 3 remaining patients (patients 3, 4, and 5)
had a more indolent clinical presentation. Patient 3 and 4
developed hypoxemia without any radiologic evidence of
parenchymal or alveolar lung disease. In fact, wheny aGVHD Infections at PAH Diagnosis
, ﬂudarabine, melphalan None Blood: negative
Nasal secretions: negative
arabine, cyclophosphamide, ATG None Blood: negative
BAL: negative
, ﬂudarabine, melphalan Skin Blood: CMV
Nasal secretions: negative
, ﬂudarabine, melphalan None Blood: adenovirus
Nasal secretions: MPV
ophosphamide, ATG None Blood: BK virus
BAL: EBV
st disease; PAH, pulmonary arterial hypertension; XLP, X-linked lympho-
FA, Fanconi anemia; MUD, matched unrelated donor; MA, myeloablative
agocytic lymphohistiocytosis; CMV, cytomegalovirus; MSD, matched sibling
n-Barr virus.
Table 2
Characteristics of PAH and Lung Pathology
Patient RV Pressure (%)
of Systemic*
Days from
HSCT to dx
of TMA
Days from
HSCT to dx
of PAH
Days from
dx of TMA
to PAH
Days from
Intubation
to dx of PAH
Days from
Intubation
to Death
PAH Therapy Status Lung Autopsy (A) or
Lung Biopsy (B)
1 92 þ91 þ169 78 1 1 iNO Dead A: Severe TMA and PAH
2 80 þ17 þ79 62 1 1 iNO
Septostomy
Dead Autopsy was not done
3 54 þ132 þ208 76 20 49 iNO Dead A: Severe TMA and PAH
In situ þ CMV
4 Not done þ15 þ71 56 33 33 iNO Dead A: Severe TMA and PAH
In situ þ adenovirus
5 60 þ149 þ250 101 1 N/A Sildenaﬁl Alive B: Constrictive bronchiolitis
Mild vasculopathy
PAH indicates pulmonary arterial hypertension; RV, right ventricle; HSCT, hematopoietic stem cell transplant; dx, diagnosis; TMA, transplant-associated
thrombotic microangiopathy; þ, days posttransplantation; iNO, inhaled nitric oxide; CMV, cytomegalovirus; N/A, not applicable.
* By echocardiogram for hypoxemia evaluation.
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initially attributed to prolonged cytomegalovirus (CMV) and
adenoviral infections, respectively. Because of difﬁculty
oxygenating while on ventilator support, they were empiri-
cally treated with iNO. Patient 3 had an echocardiogram
performed 20 days after intubation that was highly sugges-
tive of PAH (ventricular septal ﬂattening with RV pressure
54% of systemic), whereas patient 4 was diagnosed with PAH
only on autopsy. Patient 5 had prolonged BK viremia and
intermittent oxygen requirements. She underwent diag-
nostic BAL, after which she remained on mechanical venti-
lation for hypoxemia. Her echocardiogram showed an RV
pressure 60% of systemic. Diagnostic lung biopsy showed
constrictive bronchiolitis and mild vasculopathy. The patient
was treated with sildenaﬁl for 11 months and is currently
doingwell off oxygenmore than 2 years after transplantation
(Table 2). None of the patients had any radiologic lung
abnormalities when they presented with hypoxemia.
TA-TMA occurred in 13% of patients (28 of 209) under-
going HSCT during this period. Notably, in the subset that
developed hypoxemic respiratory failure and underwent
echocardiography evaluation, the occurrence of TA-TMAwas
60% (20 of 33 patients). All 5 patients diagnosed with
pulmonary hypertension had clinical evidence of active
TA-TMA for a median of 76 days (range, 56-101 days) before
developing hypoxemic respiratory failure. Acute kidneyTable 3
TA-TMA Features and Management
Clinical Features/Management Patient 1 Pati
De novo anemia and thrombocytopenia Yes Yes
LDH* 2.0 2.
Haptoglobin (normal 16-200 mg/dL) <7 <7
Schistocytesy 1þ 1þ
Creatininez 2.5 2.
GFR (mL/min)x 75 48
Proteinuriak 4 0.
Antihypertensive medications{ 6 4
Cyclosporine discontinued (d)# Yes (20) No
Rituximab use No No
Renal replacement therapy No No
Therapeutic plasma exchange No No
TA-TMA indicates transplant-associated thrombotic microangiopathy.
* LDH (lactate dehydrogenase) elevation  (times) above upper normal level fo
y 1þ is indicative of 1% to 5% of schistocytes on the grading scale using 100  o
z Serum creatinine elevation  (times) from pretransplantation baseline.
x GFR (glomerular ﬁltration rate, mL/min) based on cystatin C.
k Proteinuria by random urine protein/creatinine ratio with a ratio >2 being ne
{ Number of antihypertensive medications that the patient was receiving.
# Number of days (d) that cyclosporine was discontinued after TA-TMA diagnosinjury attributed to TA-TMA with refractory hypertension
and severe proteinuriawas present in all 5 patients, with 2 of
them requiring renal replacement therapy (Table 3). Because
there is no uniform therapeutic approach to TA-TMA therapy,
calcineurin inhibitor cyclosporine was discontinued in 3 of 5
patients 12 to 26 days after TA-TMA diagnosis, based on the
primary transplantation physician’s decision. Rituximab and
therapeutic plasma exchange were attempted for patient 3
very late in the disease course without obvious clinical
beneﬁt because of advanced organ injury. Patient 5 received
3 weekly doses of rituximab for EpsteineBarr virus infection
during active TA-TMA (Table 3).
Three of the 4 deceased patients underwent autopsies,
which demonstrated severe pulmonary vascular disease. In
all cases, lung histology was consistent with acute and
subacute TA-TMA, with endothelial separation noted in the
pulmonary arterioles, extravasation of fragmented RBC into
surrounding tissue, and formation of ﬁbrin thrombi. These
ﬁndings were associated with marked thickening of all 3
layers of the vascular wall, with up to 95% occlusion of the
arteriolar lumens in all lung pathology samples (Figure 1).
Some areas had intra-arteriolar ﬁbrin microthrombi with
focal areas of organization and recanalization suggestive of
chronic and progressive endothelial injury. Patients 3 and 4
had evidence of TA-TMA in other organs including the
kidneys. CMV and adenovirus were detected in the lungent 2 Patient 3 Patient 4 Patient 5
Yes Yes Yes
0 3.3 4.4 3.6
<7 <7 <7
1þ 1þ 1þ
8 9.0 3.5 6.8
25 40 24
5 9.9 3.5 4.4
8 4 4
No Yes (26) Yes (12)
Yes No Yes
Yes No Yes
Yes No No
r age.
bjective withw100 RBCs per ﬁeld.
phrotic range proteinuria.
is.
Figure 1. Lung histology from autopsy specimens showing histopathologic changes of transplantation-associated thrombotic microangiopathy (TA-TMA) and
pulmonary arterial hypertension (PAH). (A), Lung histology from patient 1 (1a, b, c), patient 3 (2a, b, c), and patient 4 (3a, b, c) demonstrated severe vascular disease
involving pulmonary arterioles. All 3 autopsies demonstrated different stages of severe vascular injury present in the same sample ranging from acute micro-
angiopathic vascular injury (1a, 2a, 3a) to subacute (1b, 2b, 3b), and ﬁnally severe obliterative changes consistent with histological evidence of PAH (1c, 2c, 3c)
(H&E, 40). Black arrowheads show acute and subacute signs of TMA with endothelial cells “ﬂoating” in the vascular lumen after complete separation from the
basement membrane. Transparent arrowheads indicate red cell fragments extravagated into surrounding tissues. Other vessels show thickening of all 3 layers of the
vascular wall, with up to 95% occlusion of the arteriolar lumens in all lung pathology samples (solid double headed arrows, 1c, 2c, 3c). Some areas have intra-arteriolar
ﬁbrin microthrombi (star) with focal areas of organization suggestive of chronic and progressive endothelial injury. 1b, 2b, and 3b depict subacute vascular injury with
separated endothelium (black arrowheads) and initial stages of proliferation of vascular wall (dotted double arrows). (B), Lung histology from patient 3 (H&E, 40)
illustrating different stages of vascular injury ranging from acute vascular lesions with separation of the endothelium (black arrowheads), lumen occluding ﬁbrin and
cell debris (dotted double headed arrow) with severe red cell fragmentation and extravasation into surrounding tissues (transparent arrowhead), to advanced
proliferation of vascular wall (solid double headed arrow) with ﬁbrin microthrombi with focal evidence of organization and near obliteration of vascular lumen (star).
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Autopsy in patient 1 was limited to the lungs. PAH because of
TA-TMA was the primary cause of death reported in all 3
patients’ autopsies.
DISCUSSION
We describe 5 cases of PAH in pediatric patients who
underwent HSCT after a prolonged course of untreated TA-
TMA. PAH was severe and a signiﬁcant contributor to the
death in 4 of 5 patients in our cohort. The diagnosis of PAH
became apparent only after these patients clinically wors-
ened, and in 1 patient, only at autopsy. At the time, we did
not have uniform screening guidelines for patients who
underwent HSCT with hypoxemic respiratory failure. Only
73% of patients with respiratory failure underwent echocar-
diographic evaluation, hence, we cannot comment on exact
prevalence of PAH in our pediatric HSCT population.
However, based on available data from patients who were
evaluated, pulmonary hypertension occurred in 15% (5 of 33
patients) of posttransplantation patients with respiratory
failure. It is very likely that the nonspeciﬁc presentation of
PAH and the high index of suspicion required for diagnosis
makes this complication underdiagnosed in the pediatric
HSCT population [20-22].
All 5 patients diagnosed with PAH in our study had
a prolonged history of TA-TMA. It is important to note that
TA-TMA occurred in a much higher proportion in patients
who presented with hypoxemic respiratory failure. TA-TMA
is an increasingly recognized complication after HSCT with
high associated morbidity and mortality [23]. TA-TMA typi-
cally affects renal vasculature. However, as evidenced by ourcases, TA-TMAmay be associated with signiﬁcant pulmonary
vascular injury, leading to hypoxemic respiratory failure after
HSCT. It seems plausible that the persistent endothelial
injury damaging the small blood vessels of the kidney in TA-
TMA could also affect the pulmonary vasculature. Speciﬁ-
cally, pulmonary arteriolar narrowing could be caused by
microthombi formation, ﬁbrin deposition, and damage from
RBC and platelet fragments. Persistent inﬂammation and
vasoconstriction would then promote vascular wall prolif-
eration, leading to the increased vascular resistance seen in
PAH [24-26]. An acute stressor, such as active hemolysis,
could promote vascular spasm contributing to a rapid
elevation in PA resistance, fulminant right heart failure, and
hemodynamic collapse.
It is also possible that pulmonary vascular endothelial
trauma may signiﬁcantly interrupt normal nitric oxide
production and metabolism, and alter the response of endo-
thelin receptor function [8]. Both these pathologic mecha-
nisms may have implications for treatment options [27,28].
Given our observation that 60% of patients (20 of 33) with
hypoxemic respiratory failure had evidence of TA-TMA, and
of these, 25% (5 of 20) had pulmonary hypertension, we
recommend that any pediatric patient with hypoxemic
respiratory failure after HSCT should be evaluated for TA-
TMA and PAH. This is especially important in critically ill
HSCT recipients with respiratory failure and/or shock of
unclear etiology. TA-TMA should be assessed by monitoring
for microangiopathic hemolysis with twice-weekly LDH,
weekly haptoglobin, and reviewing the daily peripheral
blood smear for schistocytes. Close attention should be given
to blood pressure and renal function, including proteinuria. If
Figure 2. Screening and follow-up algorithm for pulmonary arterial hypertension (PAH) in pediatric patients who underwent hematopoietic stem cell transplant
(HSCT). TA-TMA indicates transplantation-associated thrombotic microangiopathy.
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continued in patients with a diagnosis of TA-TMA, and
alternative immunosuppressive agents such as mycopheno-
late mofetil and/or steroids should be considered for
GVHD prophylaxis. Rituximab and therapeutic plasma
exchange had been used in patients who undergo HSCT with
successful reversal of microangiopathy reported in small
cohorts of patients, although without clear understanding
of the mechanism of action in the HSCT population, and
might be beneﬁcial in such a patient cohort if introduced
promptly [18].
Bedside transthoracic echocardiography is an easy to
perform and noninvasive screening test to rapidly assess
RV pressure and function. This should be compared to the
pretransplantation cardiopulmonary assessments. If the
screening echocardiogram is normal and respiratory failure
persists, the echocardiogram should be repeated every 1 to 2
weeks. RV pressures 35% to 49% of systemic require very
close monitoring. Patients with symptoms of pulmonary
hypertension and/or RV dysfunction (RV pressure 50%
systemic) should be immediately evaluated by the cardi-
ology/pulmonary hypertension team (Figure 2). When indi-
cated (inconclusive echocardiographic or clinical evaluation),
right heart catheterization should be strongly considered to
conﬁrm the diagnosis and test responsiveness to pulmonary
vasodilators to improve the otherwise poor outcome of PAH.
Best therapeutic options should be guided by the cardiology/
pulmonary hypertension team, because selection of appro-
priate therapies for PAH is complex and there are no stan-
dardized pulmonary vasodilator regimens for PAH therapy in
children [29,30].
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